Literature DB >> 6482756

Prevention of vertical transmission of hepatitis B. The place of routine screening in antenatal care, and the case for immunization of infants at risk.

G L Gilbert.   

Abstract

Many chronic carriers of hepatitis B virus acquire the infection from their mothers at birth; the risk is greatest if the mother either has acute hepatitis B or is a hepatitis Be antigen (HBeAg)-positive HBsAg carrier, but there is some risk also to the infants of mothers who do not carry HBeAg. At the Royal Women's Hospital, Melbourne, nearly 2% of women attending antenatal clinics are found to be carriers and, without immunization, approximately five infants per 1000 infants delivered (up to 15 infants annually) would also become carriers. Vertical transmission of hepatitis B can be prevented by a combination of passive and active immunization if infants at risk can be identified at or before birth. Routine screening for hepatitis B surface antigen in pregnant women is recommended, at least in institutions in which the patient population includes a high proportion of migrants, in whom the prevalence of hepatitis B carriage is relatively high.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6482756

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

Review 1.  Epidemiology of hepatitis B infection in the Western Pacific and South East Asia.

Authors:  I D Gust
Journal:  Gut       Date:  1996       Impact factor: 23.059

2.  Screening of pregnant women for hepatitis B markers in a French Provincial University Hospital (Limoges) during 15 years.

Authors:  François Denis; Sylvie Ranger-Rogez; Sophie Alain; Marcelle Mounier; Caroline Debrock; Anne Wagner; Christian Delpeyroux; Jean Louis Tabaste; Yves Aubard; Pierre-Marie Preux
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

3.  Prevalence of hepatitis B virus infection in pregnant women in the Montreal area.

Authors:  G Delage; S Montplaisir; S Rémy-Prince; E Pierri
Journal:  CMAJ       Date:  1986-04-15       Impact factor: 8.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.